Anti-Human CD11c [Clone 3.9] – PE

This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This R-PE conjugate is stable when stored at 2-8°C. Do not freeze.

Next Day 2-8°C

Blue Laser (488 nm) and/or Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Clone 3.9 recognizes the α-chain (CD11c) of the CD11c/CD18 complex. It is specific for the I domain of CD11c. Clone 3.9 binds the activated form of CD11c and partially blocks the binding of CD11c with ICAM-4.

LFA-1α (CD11a) and CD18 are the Integrin alpha-L and beta-2 chains respectively that combine to form LFA-1, a glycoprotein and a member of the Integrin family. Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3, ICAM4 and for F11R. LFA-1 participates in the immunological synapses between CD8+ T lymphocytes and antigen-presenting cells. The absence of LFA-1α or ß may induce LAD. The antigen contributes to natural killer cell cytotoxicity, and is involved in various immune phenomena such as leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. The CD11b/CD18 antigen is a heterodimeric surface glycoprotein on leukocytes and belongs to the ß2 integrin family. CD11b functions as a receptor for C3bi complement, clotting factor X, fibrinogen and ICAM-1. CD11c forms an α/ß heterodimeric glycoprotein (CD11c/CD18 complex) which belongs to the ß2 integrin family. The complex binds fibrinogen and reportedly serves as a receptor for iC3b and ICAM-1. During inflammatory responses, it mediates cell to cell interaction and is important in both monocyte adhesion and chemotaxis.

CD11c is primarily expressed on dendritic cells, NK cells, a subset of intestinal intraepithelial lymphocytes (IEL), and some activated T cells.

CD54, fibrinogen, iC3b, ICAM-1, ICAM-4

1. Leukocyte Typing V (1995) Oxford University Press 2. Leukocyte Typing IV (1989) Oxford University Press 3. Leukocyte Typing III (1987) Oxford University Press 4. Hogg, N. et al. (1986) Eur. J. Immunol. 16:240 5. Malhotra, V. et al. (1986) Eur. J. Immunol. 16:1117 Phycobilliproteins are protected under the following patents: (U.S. patents No. 4,520,110 and 4,542,104, European patent no. 76695, Canadian patent No. 1,179,942 and Australian patent No. 548,440).